Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Sch 1 Update - ISIS Resources

15 Sep 2006 11:23

AIM15 September 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: Verona Pharma plc (previously Isis Resources plc) COMPANY ADDRESS: Adderbury Hill Barn, Milton Road, Adderbury, Oxon COMPANY POSTCODE: OX17 3HN COUNTRY OF INCORPORATION: United Kingdom COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: The company is involved in drug discovery focused on the discovery and development of new therapeutic drugs for thetreatment of allergic rhinitis (hay fever) and other chronic respiratory and inflammatory diseases. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 144,275,000 Ordinary Shares of £0.001 each CAPITAL TO BE RAISED ON ADMISSION: £2.043 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Professor Clive Peter Page, Non-Executive Chairman Professor Michael John Alfred Walker, Chief Executive Officer Claire Louise Poll, Executive Director Professor Trevor Mervyn Jones, Non-Executive Director Herbert Stuart Bottomley, Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Prior to Admission %Craig Burton* 19.9Pershing Keen Nominees Ltd** 18.5Williams de Broe 7.0Stuart Bottomley*** 7.0Josef El Raghy 6.0Fitel Nominees Ltd a/c CO57658 5.6Jamie Boyton 4.8William Fairweather 4.6Fitel Nominees Ltd a/c CO58142 4.2Mark Freeman 4.0Tolle Investments Pty Ltd 4.0 * Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A/C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited After admission %Fidelity Euro Smaller Companies Fund 9.70Craig Burton* 8.66Pershing Keen Nominees Ltd** 6.42Williams de Broe 5.80Stuart Bottomley*** 4.16Clive Page 3.92Michael Walker 3.91David Saint 3.91Millenium Capital Partners 3.19* Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A /C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: None ANTICIPATED ACCOUNTING REFERENCE DATE: 31 December EXPECTED ADMISSION DATE: 19 September 2006 NAME AND ADDRESS OF NOMINATED ADVISER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ NAME AND ADDRESS OF BROKER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DATE OF NOTIFICATION:15 September 2006UPDATE Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jan 201210:42 amPRNResult of General Meeting
8th Dec 20112:05 pmPRNCompletion of GBP3.25 million placing
25th Nov 20113:55 pmPRNHolding(s) in Verona Pharma
10th Nov 20117:00 amPRNPositive results for COPD pilot study
3rd Nov 20117:00 amPRNWH Ireland Limited appointed as Nomad and Broker
20th Sep 20117:00 amPRNIssue of Options
7th Sep 20117:01 amPRNInterim Report for the six months ended 30 June 2011
7th Sep 20117:00 amPRNVRP700 demonstrates significant anti-tussive effects
17th Aug 20117:22 amPRNBronchodilation in asthmatics maintained with RPL554
7th Jun 20114:21 pmPRNDirector Options
3rd Jun 20113:43 pmPRNResult of AGM
3rd Jun 201111:09 amPRNAGM Statement
12th May 20117:00 amPRNStart of New Phase II Clinical Trial of RPL554
9th May 20115:29 pmPRNCorrection of AGM date
9th May 20114:13 pmPRNNotice of AGM and Issue of Annual Report
21st Apr 20117:00 amPRNAppointment of Joint Broker
12th Apr 20117:00 amPRNFirst COPD Trial with RPL554 Begins in Rome
23rd Mar 20117:00 amPRNPreliminary Unaudited Results
1st Mar 201110:24 amPRNTotal Voting Rights
22nd Feb 20111:24 pmPRNIssue of Equity
22nd Feb 20117:02 amPRNVerona Pharma announces positive results for RPL554
7th Jan 20117:00 amPRNResponse to Share Price Movement
26th Nov 20107:01 amPRNRPL554: PoC studies on industry-standard inhaler devices
26th Nov 20107:00 amPRNNew Higher Dose RPL554 Clinical Trial in Asthma
27th Oct 20107:00 amPRNVRP700 for chronic cough enters clinic
6th Sep 20107:00 amPRNHalf-yearly Report
27th Aug 20107:00 amPRNNotice of Interim Results
28th Jun 20107:00 amPRNUpdate on RPL554 and Cough Projects
18th Jun 20104:55 pmPRNGrant of Options
3rd Jun 201012:57 pmPRNResult of AGM
3rd Jun 20107:00 amPRNAGM Statement
4th May 20103:56 pmPRNNotice of AGM
26th Mar 20107:00 amPRNPreliminary Results
20th Jan 20103:52 pmPRNNotice of Interest
14th Jan 20107:00 amPRNNew Year Progress Report
7th Jan 20107:00 amPRNNotice of Interest
6th Jan 201010:37 amPRNApplication for admission of new Ordinary Shares
24th Dec 20099:13 amPRNRESULT OF GENERAL MEETING
18th Dec 20094:16 pmPRNApplication for Admission of New Ordinary Shares
15th Dec 20098:12 amPRNDirectors' Shareholding
9th Dec 20098:04 amPRNPosting of Circular
28th Oct 200911:26 amPRNNotice of interest
11th Sep 20094:57 pmPRNFurther re Board Appointment
11th Sep 20097:03 amPRNBoard Appointment
11th Sep 20097:00 amPRNRPL554 proven safe and effective in patients with asthma
4th Sep 20097:00 amPRNHalf-yearly Report
2nd Sep 20097:00 amPRNChange of Nomad
29th May 20097:00 amPRNTotal Voting Rights
22nd May 200912:01 pmPRNResult of AGM
20th May 20097:00 amPRNClinical Trial Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.